FDA orphan drug designation: treatment of neuroendocrine carcinoma
All entries for: Suzhou Zelgen Biopharmaceuticals Co.
November 13, 2025
Suzhou Zelgen Biopharmaceuticals Co.
Orphan Drug Designation
Disease Area: Rare Diseases
FDA orphan drug designation: treatment of neuroendocrine carcinoma